A Phase 2a Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn’s Disease

• Register: EUCTR
• Last refreshed on: 12 December 2023
• Main ID: EUCTR2017-003359-43-PL
• Date of registration: 24/04/2018
• Prospective Registration: Yes
• Primary sponsor: Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001
• Public title: A Phase 2a Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn’s Disease
• Scientific title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 As Induction And Open Label Extension Treatment In Subjects With Moderate To Severe Crohn’s Disease
• Date of first enrolment: 23/05/2018
• Target sample size: 255
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003359-43
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 4
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no

Countries of recruitment

Australia, Austria, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Czechia, Georgia, Germany, Hungary, Italy, Korea, Republic of, Lebanon, Lithuania, Poland, Russian Federation, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Switzerland, Tunisia, Turkey, Ukraine, United Arab Emirates, United States

Contacts

• Name: Clinical Trials.gov Call Centre
• Affiliation: Pfizer Inc

• Name: Clinical Trials.gov Call Centre
• Affiliation: Pfizer Inc

Key inclusion & exclusion criteria

Inclusion criteria:
1. Male and/or female subjects (including Women of Child Bearing Potential (WOCBP)) =18 years to =75 years of age at the time of informed consent. For subjects in Korea: Male and/or female subjects =19 years to =5 years of age at the time of informed consent.
2. Documented diagnosis of ileal, ileocolonic, or colonic CD with a minimum disease duration of 3 months, as determined by endoscopic and histopathology assessment.
3. Endoscopic (central reading) confirmation of active disease with total SES-CD total score of at least 7 (=7)). For isolated ileal disease, SES-CD total score should be at least 4 (=4).
4. An average daily liquid/soft stool frequency (SF) =2.5 or daily abdominal pain (AP) score =2.0.
5. Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD:
• Steroids;
• Immunosuppressants (azathioprine [AZA], 6-MP, or methotrexate [MTX]);
• Anti-TNF inhibitors (infliximab, adalimumab, or certolizumab);
• Anti-integrin inhibitors (eg, vedolizumab);
• Anti-IL-12/23 inhibitor (ustekinumab).
However, this inclusion should be met only after the usual clinical practice in each center has been fulfilled, which may involve administration of more than one line of previous treatment.
Note: Further guidance information related to this inclusion criteria can be found in the protocol
6. Subjects currently receiving the following treatment for CD are eligible providing they have been on stable doses as described below:
• Oral corticosteroids (prednisone or equivalent up to 25 mg/day; budesonide up to 9 mg/day; See Protocol Appendix 11). Stable dose for at least 2 weeks prior to baseline. If oral corticosteroids have been recently discontinued, they must have been stopped at least 2 weeks prior to baseline. Decreases in steroid use due to AEs are allowed.
• Oral 5-ASA or sulfasalazine are allowed providing that the dose is stable for at least 4 weeks prior to baseline.
• Crohn’s disease-related antibiotics are allowed providing that the dose is stable for at least 4 weeks prior to baseline. If antibiotics are stopped prior to baseline, they must be discontinued at least 4 days prior to baseline.
7. Female subjects of childbearing potential must test negative for pregnancy at screening visit and baseline visit.
8. Female subjects considered to be of non-childbearing potential must meet at least 1 of the following criteria:
a. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state;
b. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
c. Have medically confirmed ovarian failure.
All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
9. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 242
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 13

Exclusion criteria:
1. Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease, ulcerative colitis (UC), or clinical findings suggestive of UC.
2. Presence of active (draining) fistulae or intra-abdominal or perineal abscesses.
3. Strictures with obstructive symptoms.
4. Short bowel syndrome.
5. History of bowel perforation requiring surgical intervention within the past 12 months.
6. Previous bowel surgery resulting in an existing stoma. Subjects who have a j-pouch are excluded, as a j-pouch can result in a stoma.
7. History of bowel surgery within 6 months prior to baseline.
8. Subjects considered in imminent need for surgery or with elective surgery scheduled to occur during the study.
9. Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
10. Subjects with primary sclerosing cholangitis.
11. Subjects with evidence of colonic adenomas, dysplasia or neoplasia. However, subjects with prior history of adenomatous polyps will be eligible if the polyps or any adenomatous polyps identified on screening have been completely removed and the subjects are free of polyps at baseline per the assessment of the investigator based on the screening colonoscopy.
12. Subjects receiving the following therapies within the time period described below or expected to receive any of these therapies during the study period:
a. >9 mg/day of oral budesonide or >25 mg/day of prednisone or equivalent oral systemic corticosteroid dose within 2 weeks prior to baseline.
b. IV, IM (parenteral), or topical (rectal) treatment of 5-ASA or corticosteroid enemas/suppositories within 2 weeks prior to baseline.
c. Azathioprine, 6-mercaptopurine, or methotrexate within 2 weeks prior to baseline.
d. Anti-TNF inhibitors (or biosimilars thereof) as described below:
• Infliximab within 8 weeks prior to baseline;
• Adalimumab within 8 weeks prior to baseline;
• Certolizumab within 8 weeks prior to baseline;
e. Anti-integrin inhibitors (eg, vedolizumab) within 8 weeks prior to baseline.
f. Ustekinumab within 8 weeks prior to baseline.
g. Interferon therapy within 8 weeks prior to baseline.
h. Subjects with prior treatment with lymphocyte-depleting agents/therapies within 1 year prior to baseline (eg, CamPath® [alemtuzumab], alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation, etc).
i. Subjects who have received rituximab or other selective B lymphocyte-depleting agents within 1 year prior to baseline.
j. Subjects previously receiving leukocyte apheresis, including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.
k. Other marketed immunosuppressants or biologics with immunomodulatory properties within 3 months prior to baseline.
l. Subjects who have received other JAK inhibitors within 3 months prior to baseline.
m. Subjects who have not responded to or have been intolerant of other JAK inhibitors.
n. Other investigational procedures(s) or product(s), such as immunosuppressants used in transplantation (eg, mycophenolate mofetil, cyclosporine, rapamycin, or tacrolimus) or live (attenuated) vaccine within 30 days prior to baseline.
13. Participation in other studies involving investigational drug(s) within 30 days, or 5 half-lives of investigational product (IP) (whichever is greater), prior to study entry and/or during study participation.
14. Presence of active enteric infections (positive stool culture

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Moderate To Severe Crohn’s Disease (CD)
MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders

Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Intervention(s)

Product Name: Ritlecitinib 50 mg
Product Code: PF-06651600 50 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: PF-06651600
Current Sponsor code: PF-06651600
Other descriptive name: PF-06651600-15
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: Brepocitinib 5 mg
Product Code: PF-06700841 5 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: PF-06700841
Current Sponsor code: PF-06700841
Other descriptive name: PF-06700841-15
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: Brepocitinib 25 mg
Product Code: PF-06700841 25 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: PF-06700841
Current Sponsor code: PF-06700841
Other descriptive name: PF-06700841-15
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Timepoint(s) of evaluation of this end point: At Week 12 during the induction period.
Please refer to the schedule of activities (open label extension period) in the protocol for the timepoints during the OLE period

Main Objective: Primary Objective(s) during the Induction Period
• To evaluate the efficacy of PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib) compared to placebo at Week 12 in subjects with moderate to severe CD.

Primary Objective(s) during the Open Label Extension Period
• To assess the safety and tolerability of PF-06651600 (ritlecitinib) and PF- 6700841 (brepocitinib) therapy during open label extension period for subjects with moderate to severe CD.

Secondary Objective: During the Induction Period
• To evaluate the safety and tolerability of PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib)compared to placebo in subjects with moderate to severe CD over 12 weeks.
• To evaluate the efficacy of PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib) compared to placebo during induction of additional endoscopic endpoints in subjects with moderate to severe CD.

During the Open Label Extension Period
• To evaluate the efficacy of PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib) as maintenance therapy in subjects with moderate to severe CD.

Primary end point(s): Primary Endpoint(s) during the Induction Period
• Proportion of subjects achieving simple endoscopic score for Crohn's disease (SES-CD) 50 (=50% reduction in SES-CD from baseline) at Week 12.

Primary Endpoint(s) during the Open Label Extension (OLE) Period
• Incidence and severity of laboratory abnormalities, vital signs, 12-lead ECG, adverse events, serious adverse events and withdrawals due to adverse events.

Secondary Outcome(s)

Secondary end point(s): Secondary Endpoint(s) during the Induction Period
• Incidence and severity of laboratory abnormalities, vital signs, 12-lead ECG, adverse events, serious adverse events and withdrawals due to adverse events.
• Incidence of serious infections
• Proportion of subjects achieving clinically meaningful endoscopic improvement reduction of = 3 points from baseline in SES-CD score) at Week 12.
Mean change from baseline in SES-CD score at Week 12.
• Proportion of subjects achieving SES-CD 25 (=25% reduction in SES-CD from baseline) at Week 12.
• Proportion of subjects achieving endoscopic remission (SES-CD =2) at Week 12
• Proportion of subjects achieving mucosal healing (complete absence of ulcers) at Week 12.

Secondary Endpoint(s) during the Open Label Extension Period
• Proportion of subjects achieving clinically meaningful endoscopic improvement (CMEI response) at week 64 among subjects who achieved CMEI response at Week 12.
• Proportion of subjects achieving SES-CD 25 and SES-CD 50 at Week 64 among subjects who achieved SES-CD 25 and SES-CD 50 at week 12 respectively.

Timepoint(s) of evaluation of this end point: At various timepoints as detailed in the Schedule of Activities

Secondary ID(s)

2017-003359-43-LT

B7981007

Source(s) of Monetary Support

Pfizer Inc

Ethics review

Status: Approved
Approval date: 15/05/2018
Contact: